Valeant Buys Obagi Medical for $360 Million

MONTREAL ( TheStreet) -- Valeant Pharmaceuticals ( VRX) is acquiring Obagi Medical Products ( OMPI), a maker of dermatology and skin-care products for $360 million in cash, the companies announced Wednesday.

Under terms of the deal, Obagi will be acquired for $19.75 per share, which represents a 28% premium to the stock's Tuesday close. Valeant expects the acquisition, once completed, to be immediately accretive to earnings.

Valeant is a specialty pharmaceuticals company that has grown aggressively through acquisitions over the past several years, starting with the merger between itself and Canadian drug maker Biovail in December 2010. Since then, Valeant has expanded its pipeline of generic and branded pharmaceutical products through multiple acquisitions.

Obagi markets a portfolio of prescription skin-care products that generated $120 million in revenue last year.

Ahead of the deal announcement, Valeant shares closed Tuesday night at $71.44.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year